Lv3
300 积分 2025-12-01 加入
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
12小时前
待确认
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
10天前
已完结
Incretin-based therapies for liver disease
19天前
已完结
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice
19天前
已完结
Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation
19天前
已完结
The NLRP3 inflammasome: activation and regulation
20天前
已完结
The NLRP3 inflammasome: Mechanisms of activation, regulation, and role in diseases
20天前
已完结
Next-generation therapeutics for diabetic kidney disease
20天前
已完结
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
21天前
已完结
Mechanism of NLRP3 inflammasome promoting hepatic stellate cell activation
28天前
已完结
皖公网安备34019202002308
